Current and future treatments of secondary osteoporosis

Raquel Soriano, Sabina Herrera, Xavier Nogués, Adolfo Diez-Perez

Research output: Contribution to journalReview articleResearchpeer-review

15 Citations (Scopus)


© 2014 Elsevier Ltd. All rights reserved. Osteoporosis is commonly associated with menopause and ageing. It can, however, also be caused by diseases, lifestyle, genetic diseases, drug therapies and other therapeutic interventions. In cases of secondary osteoporosis, a common rule is the management of the underlying condition. Healthy habits and calcium and vitamin D supplementation are also generally advised. In cases of high risk of fracture, specific antiosteoporosis medications should be prescribed. For most conditions, the available evidence is limited. Special attention should be paid to possible contraindications of drugs used for the treatment of postmenopausal or senile osteoporosis. Bisphosphonates are the most widely used drugs in secondary osteoporosis, and denosumab or teriparatide have been also assessed in some cases. Important research is needed to develop more tailored strategies, specific to the peculiarities of the different types of secondary osteoporosis.
Original languageEnglish
Pages (from-to)885-894
JournalBest Practice and Research: Clinical Endocrinology and Metabolism
Issue number6
Publication statusPublished - 1 Jan 2014


  • Osteoporosis
  • Secondary osteoporosis
  • Treatment


Dive into the research topics of 'Current and future treatments of secondary osteoporosis'. Together they form a unique fingerprint.

Cite this